Radicava Will Be a New Specialty Med for Lou Gehrig's Disease

June 2019

Radicava (ra-dih-CAH-vah, edaravone) is the first med approved for Lou Gehrig's disease, or ALS, in almost 20 years.

Until now, we've only had riluzole (Rilutek) to treat this progressive, degenerative nerve disease...which eventually leads to muscle weakness, paralysis, and death.

Radicava helps slow the decline in physical function...such as speech, salivation, and swallowing.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Med Administration Help Patients Overcome Med Administration Hurdles
Practice Look for Opportunities to Develop Your Leadership Skills
Gastroenterology Don't Think of Meds as a Significant Source of Gluten
Glaucoma Keep an Eye Out for Vyzulta to Treat Open-Angle Glaucoma
Insomnia Listen for Reports of Strange Sleep Behaviors With Some Insomnia Meds
Dosage Forms Watch for Mix-Ups With Meds That Come as Both Solids and Liquids
Opioids Take Steps to Ensure Opioid Tapers Go Safely and Smoothly
Warts Sort Through Treatments for Warts
Neurology & Pain Radicava Will Be a New Specialty Med for Lou Gehrig's Disease
Diabetes Stay Alert for Med Changes When Diabetes Patients Have Surgery

Radicava Will Be a New Specialty Med for Lou Gehrig's Disease

Practical advice for a better career, with unlimited access to CE

Table of Contents